Abstract:Background Osteoclast excessive activation was closely related to bone diseases such as osteoporosis and rheumatoid arthritis. Sec-O-glucosylhamaudol (SOG), an active flavonoid compound derived from the root of divaricate Saposhnikovia , was reported to exhibit analgesic, anti-inflammatory and high 5-lipoxygenase (5-LO) inhibitory effects. However, its effect on osteoclastogenesis and bone resorption remained unclear. Methods Osteoclast formation, bone resorption pit area formation and F-actin ring formation were examined by TRAP staining, modified Vonkonsa staining and immunofluorescence, respectively. RT-Realtime PCR assay and western blot analysis were performed. siRNA transfection was conducted to silence the expression of 5-LO in cells. LPS-induced bone-loss mice model was prepared and the left and right femurs were collected for Micro-CT and histomorphometric analysis, respectively. Results SOG markedly attenuated RANKL-induced osteoclastogenesis through decreasing TRAP activity, F-actin ring formation and bone resorption with reduction of mRNA levels of osteoclastogenesis marker genes such as TRAP, CTSK and DC-STAMP. Our results further indicated that SOG markedly reduced the induction of key transcription factors NFATc1 and c-Fos at both mRNA and protein levels during osteoclastogenesis. In addition, SOG treatment did not alter the transient phosphorylation of NF-κB p65 subunit and MAPKs (p38, ERK1/2 and JNK), AKT and GSK3β by RANKL. Interestingly, our results showed that SOG significantly inhibited the phosphorylation of AKT and GSK3β at middle-late stage of osteoclastogenesis, but did not alter calcineurin catalytic subunit PP2B-Aα expression. GSK3β inhibitor SB415286 could partly reverse inhibition of osteoclastogenesis by SOG. 5-LO knockdown at BMMs also markedly reduced RANKL-induced osteoclastogenesis. In consistent with in vitro results，SOG could significantly improve bone destruction in LPS-induced mice model. Conclusions SOG attenuated formation and function of osteoclast through suppressing AKT-mediated GSK3β inactivation, and 5-LO catalytic activity. Moreover, SOG prevented LPS-induced bone loss in mice through inhibiting osteoclastogenesis. Taken together, this study provided the evidence that SOG may have a potential therapeutic effect on osteoclast-related bone lysis disease.

Streptolysin O Derived from Streptococcus Pyogenes Inhibits RANKL‑induced Osteoclastogenesis Through the NF‑κB Signaling Pathway.

Inhibition of Pyroptosis Attenuates Staphylococcus Aureus-Induced Bone Injury in Traumatic Osteomyelitis.

Sec-O-glucosylhamaudol Inhibits RANKL-induced Osteoclastogenesis Via Repressing 5-LO and AKT/GSK3β Signaling

IL-1R/TLR2 Through MyD88 Divergently Modulates Osteoclastogenesis Through Regulation of Nuclear Factor of Activated T Cells C1 (nfatc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1)

Carnosol Attenuates RANKL-induced Osteoclastogenesis in Vitro and LPS-induced Bone Loss.

Luteolin Binds Streptolysin O Toxin and Inhibits Its Hemolytic Effects and Cytotoxicity

Stachydrine prevents LPS-induced bone loss by inhibiting osteoclastogenesis via NF-κB and Akt signalling.

Molecular Mechanism of the Bifunctional Role of Lipopolysaccharide in Osteoclastogenesis*

The Mechanism of Osteoprotegerin-Induced Osteoclast Pyroptosis In Vitro

Epothilone B prevents lipopolysaccharide-induced inflammatory osteolysis through suppressing osteoclastogenesis via STAT3 signaling pathway

TLR2-dependent Modulation of Osteoclastogenesis by Porphyromonas Gingivalis Through Differential Induction of NFATc1 and NF-κB

Dual Modulation of Osteoclast Differentiation by Lipopolysaccharide

Stimulation of osteoclast differentiation by lipopolysaccharide

Cellular Study of the LPS-induced Osteoclastic Multinucleated Cell Formation from RAW264.7 Cells.

An anti-perfringolysin O monoclonal antibody cross-reactive with streptolysin O protects against streptococcal toxic shock syndrome

Zoledronic Acid Inhibits Osteoclastogenesis and Bone Resorptive Function by Suppressing RANKL‑mediated NF‑κB and JNK and Their Downstream Signalling Pathways.

Staphylococcal protein A promotes osteoclastogenesis through MAPK signaling during bone infection.

RANKL-mediated osteoclast formation is required for bone loss in a murine model of Staphylococcus aureus osteomyelitis

Nirogacestat Suppresses RANKL-Induced Osteoclast Formation in Vitro and Attenuates LPS-Induced Bone Resorption in Vivo.

Glycyrrhizin Suppresses RANKL-Induced Osteoclastogenesis and Oxidative Stress Through Inhibiting NF-κB and MAPK and Activating AMPK/Nrf2

Inhibitory Effect of LGS and ODE Isolated from the Twigs of Syringa oblata subsp. dilatata on RANKL-Induced Osteoclastogenesis in Macrophage Cells